Interview With Kelsey Ramsden, President and CEO of Mind Cure

Kelsey Ramsden, the President, and CEO of Mind Cure Health Inc. sheds light on the advancements Mind Cure is currently making.

Psychedelic Spotlight

Numinus CEO Discussion: a LEADER in Psychedelic-Assisted Therapy? ( NUMI / LKYSF Stock)

July 11, 2021June 2, 2024 Listen, Videos

Numinus Wellness (TSX.V: NUMI), (OTC: LKYSF), has been a constant topic of conversation on this channel. NUMI is a company working on psychedelic-assisted therapy: with MDMA for PTSD, in collaboration with MAPS; Ketamine Therapy for Depression; and Psilocybin therapy for addiction, That’s why we decided to invite NUMI’s CEO, Payton Nyquvest. I hope you all enjoy!

Timestamps
1:00 – What is Numinus’ mission?
2:37 – Numinus’ partnership with MAPS to treat PTSD with MDMA
9:54 – Numinus treating addiction with Psilocybin
13:35 – Using ketamine to treat Depression
18:45 – Growing natural Psilocybin vs Synthetic versions?
21:45 -The 5-year plan
26:38 – What will revenues look like?

Enjoy the episode!

Check out our website:
ThePsychedelicInvestor.com

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Numinus #NUMIStock
#numinus #numi #numistock

Interview with Sam Chapman, Executive Director of the Healing Advocacy Fund

May 12, 2022June 2, 2024 Listen, Podcasts

This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.

Interview With Laura Dawn

August 11, 2021June 2, 2024 Listen, Podcasts

In today’s episode of the Psychedelic Spotlight podcast, we feature Laura Dawn- a microdosing mentor, visionary life coach, business consultant, author, international speaker, and host of the Psychedelic Leadership podcast.

Interview with Joseph Mays, IRI Program Director at Chacruna

October 13, 2021June 2, 2024 Listen, Podcasts

In our conversation with Joseph, we chat a bit about some critical topics such as how psychedelics can allow us to understand the Indigenous philosophy of interrelatedness between one another and our ecosystems, the importance of considering sacred reciprocity to Indigenous peoples and their land, and how Chacruna’s Indigenous Reciprocity Initiative is making it simple for companies to give back to the societies who have cultivated psychedelic medicine.

Cathie Wood and ARK Invest Buy a Psychedelic Stock!!! | $ARKG | Initial Reaction 🍄🍾

February 10, 2022June 2, 2024 Listen, Videos

GUYS. IT HAPPENED. Cathie Wood and ARK Invest have invested in a Psychedelic Stock! Specifically, ARKG, or the ARK Genomic Revolution ETF have purchased atai Life Sciences (Nasdaq: atai)!

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Last year, the Psychedelic Investor and the Reddit Page “ShroomStocks” managed to get the question of “would you ever invest in Psychedelic Stocks” asked to Cathie Wood of ARK Invest, and her answer was a dismissive NO. She said that ARK did not invest in binary stocks, though Kevin O’Leary, who was on the same panel disagreed.

Well, it seems that time (and maybe Kevin O’Leary) have changed her mind. On Wednesday, February 9th, it was revealed that the Ark Genomic Revolution ETF, ticker symbol ARKG, had purchased 83,278 shares of ATAI.

And while this only represents 0.01% of that fund’s total holdings, it does represent a big moment for the entire psychedelics industry. For better or worse, Cathie Wood has a huge voice among investors who like growth stocks, and next-generation technology stocks, which psychedelic stocks definitely represent.

This will likely put more focus, not only on atai, but the entire psychedelics sector. I would not be surprised if companies such as MindMed (MMEDF) and Cybin (CYBN) also benefit from this. Perhaps, in the future, Ark will also buy these companies.

Hopefully, this is but an opening position, and ARKG continues to buy psychedelic stocks such as atai and MindMed. Ideally, I would also like to see the flagship ETF, ARKK, also invest in psychedelic Stocks.

#CathieWood #ARKG #PsychedelicStocks

HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market? [ +Horizons ETF UPDATE]

April 10, 2021June 2, 2024 Listen, Videos

Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. This segment is entitled “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more.

In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

1. The Effects of Treating Depression with Psilocybin
2. Taking Psychedelics in a Ritual Setting
3. Microdosing study

After covering the pertinent aspects of these studies, we’ll take a look at Americans’ ability to buy Horizons’ ETF and finally we’ll give you some updates on some decriminalization efforts.

So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…

https://benzinga.grsm.io/thepsychedel
…
Timestamps:
0:00 – Intro
1:24 – Effects of Treating Depression with Psilocybin
4:03 – Effects of Taking Psychedelics in A Ritual Setting
7:23 – Exploring the relationship between microdosing, personality & emotional insight
9:36 – Americans May be able to invest in Horizon’s ETF
11:42 – Progress on California’s bill that would LEGALIZE Possession of Psychedelics
12:57 – Massachusetts Approves Psychedelics Decimalization

General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.

#MindMed #psychedelics #shroomboom